Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Consolidated Net Income fell 26279.32% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 13932.5%. This contributed to the annual value of -$110.0 million for FY2024, which is 2817.25% down from last year.
  • As of Q3 2025, Viking Therapeutics' Consolidated Net Income stood at -$90.8 million, which was down 26279.32% from -$65.5 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Consolidated Net Income ranged from a high of -$12.4 million in Q4 2021 and a low of -$90.8 million during Q3 2025
  • In the last 5 years, Viking Therapeutics' Consolidated Net Income had a median value of -$19.6 million in 2022 and averaged -$27.4 million.
  • Per our database at Business Quant, Viking Therapeutics' Consolidated Net Income plummeted by 1044.42% in 2023 and then crashed by 26279.32% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Consolidated Net Income stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 156.51% to -$90.8 million in 2025.
  • Its Consolidated Net Income was -$90.8 million in Q3 2025, compared to -$65.5 million in Q2 2025 and -$45.6 million in Q1 2025.